Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)

Por um escritor misterioso

Descrição

Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of  Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Inhibition of Diacylglycerol Acyltransferase 2 Versus
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of  Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Beyond triglyceride synthesis: the dynamic functional roles of
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of  Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Full article: Patent landscape for discovery of promising
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of  Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
BMS-963272Cas# 1441057-15-3
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of  Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Diseases, Free Full-Text
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of  Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of  Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
PDF] MGAT2, a Monoacylglycerol Acyltransferase Expressed in the
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of  Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of  Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Inhibition of MGAT2 modulates fat‐induced gut peptide release and
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of  Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
MGAT2 inhibitor decreases liver fibrosis and inflammation in
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of  Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Metabolomics combined with network pharmacology exploration
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of  Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
The monoacylglycerol acyltransferase pathway contributes to
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of  Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Frontiers New insights into the role of dietary triglyceride
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of  Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Frontiers New insights into the role of dietary triglyceride
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of  Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Ablation of the deubiquitinase USP15 ameliorates nonalcoholic
de por adulto (o preço varia de acordo com o tamanho do grupo)